Science News
from research organizations

Brown fat found to be at the root of cancer-related wasting syndrome

Date:
July 17, 2014
Source:
Cell Press
Summary:
Many patients with advanced stages of cancer, AIDS, tuberculosis, and other diseases die from a condition called cachexia, which is characterized as a 'wasting' syndrome that causes extreme thinness with muscle weakness. Cachexia is the direct cause of roughly 20 percent of deaths in cancer patients. While boosting food intake doesn't help, and no effective therapies are available, new research points to a promising strategy that may stimulate weight gain and muscle strength.
Share:
       
FULL STORY

Many patients with advanced stages of cancer, AIDS, tuberculosis, and other diseases die from a condition called cachexia, which is characterized as a "wasting" syndrome that causes extreme thinness with muscle weakness. Cachexia is the direct cause of roughly 20% of deaths in cancer patients. While boosting food intake doesn't help, and no effective therapies are available, new research in the Cell Press journal Cell Metabolism points to a promising strategy that may stimulate weight gain and muscle strength.

The research relates to a process that has been gaining considerable attention as a way to combat obesity: the browning of white fat. While white fat normally stores calories, brown fat burns them and generates heat in the process. Therefore, efforts to turn white fat into brown fat may help people lose weight.

Erwin Wagner, of the Spanish National Cancer Research Centre in Madrid, and his colleagues found that in mice and patients with cancer-associated cachexia, white fat undergoes significant changes and turns into calorie-burning brown fat. The transformation leads to increased energy consumption and organ wasting.

The team also discovered that inflammation plays an important role in turning white fat into brown fat during cancer-associated cachexia, which suggests a potential therapeutic target. Indeed, anti-inflammatory therapies, including the nonsteroidal anti-inflammatory drug (NSAID) Sulindac, ameliorated the severity of cachexia in mice.

"Our data suggest that inhibition of the browning of white fat represents a promising approach to ameliorate the severity of cachexia in cancer patients," says Dr. Wagner. "In addition, identifying biomarkers of browning at early stages of cancer development could help to predict which patients are going to develop cachexia and are good candidates to benefit from a preventive treatment."


Story Source:

The above post is reprinted from materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michele Petruzzelli, Martina Schweiger, Renate Schreiber, Ramon Campos-Olivas, Maria Tsoli, John Allen, Michael Swarbrick, Stefan Rose-John, Mercedes Rincon, Graham Robertson, Rudolf Zechner, Erwin F. Wagner. A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell Metabolism, 2014; DOI: 10.1016/j.cmet.2014.06.011

Cite This Page:

Cell Press. "Brown fat found to be at the root of cancer-related wasting syndrome." ScienceDaily. ScienceDaily, 17 July 2014. <www.sciencedaily.com/releases/2014/07/140717124838.htm>.
Cell Press. (2014, July 17). Brown fat found to be at the root of cancer-related wasting syndrome. ScienceDaily. Retrieved August 28, 2015 from www.sciencedaily.com/releases/2014/07/140717124838.htm
Cell Press. "Brown fat found to be at the root of cancer-related wasting syndrome." ScienceDaily. www.sciencedaily.com/releases/2014/07/140717124838.htm (accessed August 28, 2015).

Share This Page: